The diagnostic implications of microbiome markers in tissue and liquid biopsies are endless. As the only cancer diagnostic company focused on developing an LDT technology platform that uses the microbiome to help detect early-stage cancer, Micronoma is developing this method using minimally invasive blood samples.
Oncobiota™ Platform Design Overview
Start with as little as 400ul of plasma
Micronoma Sample Prep
Extract nucleic acid, prepare NGS library prep and controls for maximum contamination elimination (noise reduction)
NGS on Existing Platforms
Generate NGS shotgun data with proprietary analysis methods – 6 patents filed
Cancer/Non Cancer Likelihood Report
Provide actionable results with clinically relevant performances. Lung cancer example:
– Sensitivity (88%)*
– Specificity (93%)*
*Poore, G. D., et.al (2020). Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature, 579(7800), 567–574. https://doi.org/10.1038/s41586-020-2095-1
Our patent-pending Oncobiota™ platform is designed to reveal cancer-related microbiome signatures [or biomarkers] with high specificity and sensitivity.*
Our minimally invasive and high-precision microbiome-driven liquid biopsy™ method is designed to help detect cancer even in its earliest stages. Micronoma’s patent-pending method, analyzing a multitude of circulating microbial markers linked to the tumor tissue as well as the host response to the cancer, has the potential to provide an advantage in early-stage cancer detection.
We are developing Oncobiota™ so it can be applied to many cancer types. Starting with lung cancer, which has a need for early detection and with one of the highest incidences and mortality rates, we can make a big difference in the lives of the many patients affected each year. In addition, current standard of care for lung cancer detection (low dose CT scan) is plagued with a high rate of false positives (94.5%), leading to unnecessary lung tissue biopsies.* With a lower rate of false positives, we believe the Micronoma platform has the opportunity to significantly reduce the risk and cost of lung cancer diagnosis.
*Mazzone P. (2012). The rationale for, and design of, a lung cancer screening program. Cleveland Clinic journal of medicine, 79(5), 337–345. https://doi.org/10.3949/ccjm.79a.12018
Potential Advantages Over Traditional Liquid Biopsy
A genetic sequencing-based liquid biopsy usually refers to a test done on a sample of blood to look for one or more genetic biomarker(s) associated with a cancer, such as methylation or fragmentation profile of genetic materials isolated from circulating tumor cells (CTC) and/or cell-free DNA that is shed from the tumor.
However, these types of genetic biomarkers are more easily detected for large tumors, which makes such methods less efficient for detecting cancer at its earliest stages.*
At Micronoma, we focus on the circulating microbial nucleic acid signatures, or microbiome biomarkers, that are associated with the tumor and the body’s response to the developing tumor. Importantly, and based on published data, these microbial signals do not seem to be dependent on tumor size, potentially enabling our proprietary platform to detect cancer at an earlier stage of cancer development.
*Avanzini, S. et.al. (2020). A mathematical model of ctDNA shedding predicts tumor detection size. Science advances, 6(50), eabc4308. https://doi.org/10.1126/sciadv.abc4308
Humans and Microbes
Humans and microbes co-exist in a mutually beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues, and blood, even when we are healthy.
The microbiome is the community of all the microbes—bacteria, fungi, protozoa, and viruses—that live on and inside the human body. The composition of the microbiome changes with many factors such as location in the body, lifestyle, and gender. If analyzed properly, the microbiome can reveal the status of our health.
Microbes and Cancer
Microbes are now known to be found in human tissues, including cancer tissues and blood. Micronoma’s proprietary platform and global expertise allow for the development of innovative LDTs for identification of microbial signatures in circulating blood that are predictive of a cancerous tumor. This type of minimally invasive liquid biopsy LDT uses blood samples, which can be more easily collected than solid tissue samples.
Platform Design Overview
draw to collect samples
research, discovery, and
NEXT GEN SEQUENCING
Using genomic sequencing to
pipelines to decipher and